CN Patent

CN116867771B — 噁二唑取代的螺环类化合物及其应用

Assigned to Nanchang Hongyi Technology Co Ltd · Expires 2025-08-26 · 1y expired

What this patent protects

提供了一系列式(Ⅰ)所示化合物或其药学上可接受的盐。所述化合物可用于制备治疗1‑磷酸鞘氨醇受体1相关疾病的药物，例如自身免疫性疾病或炎症。

USPTO Abstract

提供了一系列式(Ⅰ)所示化合物或其药学上可接受的盐。所述化合物可用于制备治疗1‑磷酸鞘氨醇受体1相关疾病的药物，例如自身免疫性疾病或炎症。

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: CN116867771B
Jurisdiction: CN
Classification: —
Expires: 2025-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Nanchang Hongyi Technology Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.